Search Result

Isoforms Recommended:	Cleavable Linker

Results for "

Cleavable,linker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (4) ADC Linker (40) ADC Payload (2) Akt (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (17) Apoptosis (4) Bacterial (1) Biochemical Assay Reagents (2) Btk (1) Carbonic Anhydrase (1) CD276/B7-H3 (2) DNA Alkylator/Crosslinker (1) Drug-Linker Conjugates for ADC (30) EGFR (7) FGFR (1) HSP (1) Interleukin Related (1) Microtubule/Tubulin (7) mTOR (2) N-myristoyltransferase (2) Notch (1) PARP (1) PI3K (2) PROTAC-Linker Conjugates for PAC (1) TAM Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (12) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (93) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (2)
Click Chemistry:	ADC Synthesis (4) DBCO (3) Azide (3)

100

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-20336

Mc-Val-Cit-PABC-PNP Maximum Cited Publications 6 Publications Verification Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate	ADC Linker	Others Inflammation/Immunology Cancer
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .

HY-P9985

Disitamab vedotin 5 Publications Verification RC48	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .

HY-41189

Fmoc-Val-Cit-PAB-PNP	ADC Linker	Cancer
Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers .

HY-153180

PB038	Drug-Linker Conjugates for ADC	Cancer
PB038 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-44235

MC-Gly-Gly-Phe	ADC Linker	Cancer
MC-Gly-Gly-Phe is a cleavable linker used for antibody-drug conjugates (ADC).

HY-101162

SGD-1910	Drug-Linker Conjugates for ADC	Cancer
SGD-1910 is a *agent-linker* conjugate for ADC** by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala .

HY-115524

DBCO-NHS ester 2	ADC Linker	Cancer
DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry[1]. DBCO-NHS ester 2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-153360

MC-GGFG-AM-(10Me-11F-Camptothecin)	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P99101

Vobramitamab AEX-4089; MGC026 antibody	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-W011561

Boc-NH-C6-Br	ADC Linker	Cancer
Boc-NH-C6-Br is a non-cleavable linker used for antibody-drug conjugates (ADC) .

HY-44980

Fmoc-Gly-NH-CH2-acetyloxy	ADC Linker	Cancer
Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-126681

SC-VC-PAB-MMAE 2 Publications Verification NHS-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-MMAE (NHS-VC-PAB-MMAE) is a *agent-linker* conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .

HY-173639

AZD0516	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .

HY-126498

PDEC-NB	ADC Linker	Cancer
PDEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (ADC).

HY-W071967

Alloc-Val-Ala-pAB	ADC Linker	Cancer
Alloc-Val-Ala-PAB is a peptide cleavable linker used in the synthesis of antibody-drug conjugates (ADCs). The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.

HY-126350

CL2-SN-38 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
CL2-SN-38 is a cleavable linker-based *agent-Linker* conjugate**, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer .

HY-132257

Rovalpituzumab tesirine SC-002	Antibody-Drug Conjugates (ADCs) Notch	Cancer
Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC) .

HY-P99683

Ladiratuzumab vedotin SGN-LIV1A	Antibody-Drug Conjugates (ADCs)	Cancer
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC₅₀: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .

HY-157813

2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a *drug-linker* conjugates for ADC*, consiting of a cleavable linker* and Exatecan (HY-13631). 2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan can be linked to anti-Her3 antibody .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-W190943

Azido-PEG4-Val-Cit-PAB-MMAE 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-176765

DBCO-PEG4-VA-PABC-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DBCO-PEG4-VA-PABC-MMAE is a *drug-linker* conjugate for ADC. DBCO-PEG4-VA-PABC-MMAE consists of a tubulin** inhibitor (MMAE) (HY-15162) and a cleavable linker (DBCO-PEG4-VA-PABC). DBCO-PEG4-VA-PABC-MMAE can be used for synthesis of ADC ABBV-400 (HY-171945) .

HY-164762

Trastuzumab rezetecan SHR-A1811	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-174304

Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide	Drug-Linker Conjugates for ADC	Cancer
Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide is a *drug-linker* conjugates for ADC*. Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide consists of Triptolide (HY-32735) and a stable cleavable linker* (Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-Cl) (HY-174810). Bis (vinylsulfonyl) piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide can be used for the synthesis of antibody-drug conjugates (ADCs) .

HY-157763

Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1	PROTAC-Linker Conjugates for PAC Btk	Cancer
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .

HY-128929

Fmoc-PEA	ADC Linker	Cancer
Fmoc-PEA (Example 1-2) is a used as a cleavable linker for antibody-drug conjugates (ADC) .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-132261

AcBut 4-(4-Acetyl-phenoxy)-butyric acid	ADC Linker	Cancer
AcBut (4-(4-Acetyl-phenoxy)-butyric acid) is a cleavable linker for Ozogamicin synthesis, and Ozogamicin is a drug-linker conjugate for ADC .

HY-171931A

Aminocaproyl-Val-Cit-PABC-Exatecan TFA	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a *drug-linker* conjugate for ADC*, consiting of a cleavable linker* (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis .

HY-W109224

3,3'-(Propane-2,2-diylbis(sulfanediyl))dipropionic acid	ADC Linker	Cancer
3,3'-(Propane-2, 2-Diylbis (sulfanediyl))dipropionic acid is a ROS-sensitive cleavable linker that can be used in the synthesis of ADCs. 3,3'-(Propane-2,2-diylbis(sulfanediyl))dipropionic acid is promising for research of tumor drug delivery systems .

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .

HY-177495

LD-38	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
LD-38 is a *drug-linker* conjugate for ADC. LD-38 consists of a topoisomerase 1** inhibitor (Exatecan) (HY-13631) and a highly hydrophilic stable and cleavable linker. LD-38 can be used for synthesis of ADCs, such as KA-3123-LD38 .

HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib	Drug-Linker Conjugates for ADC EGFR	Cancer
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-153947

PB089	Drug-Linker Conjugates for ADC	Cancer
PB089 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan .

HY-171931

Aminocaproyl-Val-Cit-PABC-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan is a *drug-linker* conjugate for ADC*, consiting of a cleavable linker* (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-126530

PPC-NB	ADC Linker	Cardiovascular Disease Cancer
PPC-NB is a glutathione cleavable linker used for the antibody-drug conjugate (ADC) .

HY-115545

DBCO-NHS ester 3	ADC Linker	Cancer
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC) . DBCO-NHS ester 3 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-176807

DBCO-HS-PEG2-VA-PABC-SG3199	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
DBCO-HS-PEG2-VA-PABC-SG3199 is a *drug-linker* conjugate for ADC*. DBCO-HS-PEG2-VA-PABC-SG3199 consists of a SG3199 (HY-101161) based DNA small channel crosslinker and cleavable linker. DBCO-HS-PEG2-VA-PABC-SG3199 can be used for synthesis of ADCs* .

HY-145636

Vobramitamab duocarmazine AEX4089DC1; MGC018	Antibody-Drug Conjugates (ADCs)	Cancer
Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .

HY-156691A

TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is a *drug-linker* conjugates for ADC*>. TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is the hydrochloride form of TLR7/8 agonist 4 hydroxy-PEG6-acid. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a non-cleavable linker* Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs .

HY-175216

Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 is a *drug-linker* conjugate for ADC. Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 consists of a topoisomerase 1** inhibitor (Topi MF-6) (HY-175203) and a cleavable linker (Maleimide-Ph(3,5-F)-PEG4-Val-Ala) (HY-175218). Maleimide-Ph(3,5-F)-PEG4-Val-Ala-MF-6 can be used for synthesis of ADCs .

HY-145736A

β-Glucuronide-dPBD-PEG5-NH2 TFA	Drug-Linker Conjugates for ADC Apoptosis	Cancer
β-Glucuronide-dPBD-PEG5-NH2 TFA is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD.β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2 TFA, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 TFA can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 TFA has antitumor activity .

HY-129365

SNPB	ADC Linker	Cancer
SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-129376

Sulfo-SNPB	ADC Linker	Cancer
Sulfo-SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-175272

DBCO-PEG8-VKG-CPT2	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
DBCO-PEG8-VKG-CPT2 is a *drug-linker* conjugate for ADC. DBCO-PEG8-VKG-CPT2 consists of a topoisomerase 1** inhibitor (7-MAD-MDCPT) (HY-132162) and a stable and cleavable linker (DBCO-PEG8-VKG) (HY-175426). DBCO-PEG8-VKG-CPT2 can be used for synthesis of ADCs .

Cat. No.	Product Name	Type

HY-173639

AZD0516

Fluorescent Dyes

AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .

HY-164762

Trastuzumab rezetecan SHR-A1811	Fluorescent Dyes
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .

HY-172820

Trastuzumab envedotin

DP303c

Fluorescent Dyes

Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy	Fluorescent Dyes
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

Cat. No.	Product Name	Target	Research Area

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P4139

activable cell-penetrating peptide (ACCP)	Peptides	Others
activable cell-penetrating peptide (ACCP) consists of a polycationic CPP (typically arg9 or r9) connected via a cleavable linker to a matching polyanion (typically glu9 or e9), which reduces the net charge to nearly zero and thereby inhibits adhesion and uptake into cells .

HY-P11804

DTyr-Gly-DTyr-Gly	ADC Linker	Cancer
DTyr-Gly-DTyr-Gly is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P11805

Gly-Gly-DTyr-Gly-Gly	ADC Linker	Cancer
Gly-Gly-DTyr-Gly-Gly is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P11807

DArg-DLys-DTyr-DTyr-Gly-DTrp	ADC Linker	Cancer
DArg-DLys-DTyr-DTyr-Gly-DTrp is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-P11806

DLeu-DTyr-Gly-DTrp-Gly-DTyr-DTrp	ADC Linker	Cancer
DLeu-DTyr-Gly-DTrp-Gly-DTyr-DTrp is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P99101

Vobramitamab AEX-4089; MGC026 antibody	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-141599

Camidanlumab tesirine ADCT 301	Antibody-Drug Conjugates (ADCs) Interleukin Related	Cancer
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .

HY-P992130

Rolditamig TQB2102 Antibody	ADC Antibody EGFR	Cancer
Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 (HER2) antibody. Rolditamig can be conjugated with an enzyme-cleavable linker and a topoisomerase I inhibitor to form the ADC TQB2102. Rolditamig is applicable to research on solid tumors such as HER2-positive breast cancer .

HY-P992322

BAY-79-4620 Antibody	ADC Antibody Carbonic Anhydrase	Cancer
BAY-79-4620 Antibody is a potent and selective CAIX antibody with a human CAIX K_d of 3.6 nM. BAY-79-4620 Antibody yields antibody-drug conjugate (ADC) through conjugating with Monomethyl auristatin E (HY-15162) via a self-immolative enzyme-cleavable linker. BAY-79-4620 Antibody can be used for the research of cervical carcinoma, non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, gastric carcinoma, prostate carcinoma .

Cat. No.	Product Name		Classification

HY-115524

DBCO-NHS ester 2		ADC Synthesis DBCO
DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry[1]. DBCO-NHS ester 2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-W190943

Azido-PEG4-Val-Cit-PAB-MMAE 1 Publications Verification		Azide ADC Synthesis
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-176765

DBCO-PEG4-VA-PABC-MMAE		DBCO
DBCO-PEG4-VA-PABC-MMAE is a *drug-linker* conjugate for ADC. DBCO-PEG4-VA-PABC-MMAE consists of a tubulin** inhibitor (MMAE) (HY-15162) and a cleavable linker (DBCO-PEG4-VA-PABC). DBCO-PEG4-VA-PABC-MMAE can be used for synthesis of ADC ABBV-400 (HY-171945) .

HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib		ADC Synthesis Azide
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-115545

DBCO-NHS ester 3		ADC Synthesis DBCO
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC) . DBCO-NHS ester 3 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-131088A

N3-PEG8-Phe-Lys-PABC-Gefitinib TFA		Azide
N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (HY-50895) (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib TFA is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy	ADC Linker	Cancer
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: